Amylin as a Future Obesity Treatment
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Obesity is defined as abnormal or excessive fat accumulation that contributes to detrimental health impacts. One-third of the population suffers from obesity, and it is important to consider obesity as a chronic disease requiring chronic treatment. Amylin is co-secreted with insulin from β pancreatic cells upon nutrient delivery to the small intestine as a satiety signal, acts upon sub-cortical homeostatic and hedonic brain regions, slows gastric emptying, and suppresses post-prandial glucagon responses to meals. Therefore, new pharmacological amylin analogues can be used as potential anti-obesity medications in individuals who are overweight or obese. In this narrative review, we analyse the efficacy, potency, and safety of amylin analogues. The synthetic amylin analogue pramlintide is an approved treatment for diabetes mellitus which promotes better glycaemic control and small but significant weight loss. AM833 (cagrilintide), an investigational novel long-acting acylated amylin analogue, acts as a non-selective amylin receptor. This calcitonin G protein-coupled receptor agonist can serve as an attractive novel treatment for obesity, resulting in reduction of food intake and significant weight loss in a dose-dependent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Amylin is co-secreted with insulin from pancreatic β-cells in response to food intake, delays gastric emptying, inhibits glucagon secretion, improves glycaemia, increases satiety, and reduces food intake without decreasing energy expenditure (appendix p 6), [146][147][148] with a mode of action that differs from GLP-1.149”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Amylin acts on amylin receptors in the brainstem to reduce food intake [83] and improves glucose metabolism by delaying gastric emptying and inhibiting glucagon secretion [84, 85].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“As WL with GLP-1 RA and amylin analogues results both from distinct and overlapping pathways, a combination of these entero-pancreatic hormones may induce a synergistic WL effect [84].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [84]
In the citing paper
“It slows down the gastric emptying and inhibits the glucagon secretion – both these actions improve glycemia [60].”
In the citing paper
“Amylin is a pancreatic hormone secreted by β-cells in response to food intake.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Obesity Stigma: Important Considerations for Public Health
Puhl, R. M., & Heuer, C. A. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.159491 · Cited by 1,917
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Mechanisms underlying weight loss after bariatric surgery
Miras, A. D., & le Roux, C. W. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.119 · Cited by 344
Self-citationEnebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316 · cited 1×
“…104.7± 19.2 106.9± 22.1 108.1± 17.2 104.0± 17.8 43.0± 11.0 46.0± 12.0 45.0± 14.0 44.0± 14.0 44.0± 12.0 46.0± 13.0 47.0± 12.0 73 71 72 75 71 73 73 Yes Yes Yes Yes Yes Yes NA Enebo et al. (2021)14 20 Randomized, placebo controlled 0.16 mg cagrilintide+2.4 mg semaglutide 0.30 mg cagrilintide+2.4…”
InfluentialLau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01751-7 · Cited by 278 · cited 1×
“…14.3 103.2± 17.8 49.9± 9.0 51.0± 8.0 50 50 Yes NA Aronne et al. (2007)30 16 Double-blind, placebo controlled 240 µg tid Placebo 137 67 37.9± 5.7 37.6± 5.5 105.5± 18.4 104.9± 19.1 48.0± 10.0 19.0± 10.0 80 81 Yes NA Lau et al. (2021)15 26 Double-blind, placebo controlled 0.3 mg cagrilintide once…”
InfluentialSelf-citationAmylin Agonists: A Novel Approach in the Treatment of Diabetes
Schmitz, O., Brock, B., & Rungby, J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s233 · Cited by 239
Lutz, T., Mollet, A., Rushing, P., Riediger, T., & Scharrer, E. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801664 · Cited by 223
Cited by
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Amylin acts on amylin receptors in the brainstem to reduce food intake [83] and improves glucose metabolism by delaying gastric emptying and inhibiting glucagon secretion [84, 85].”
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
“129 It functions as a satiety signal, acting upon brain regions involved in both homeostatic and hedonic appetite regulation; it also slows the gastric emptying, and thereby suppresses post-prandial glucagon responses to meals.”
Background
Metadata
- Authors
- Dehestani, B., Stratford, N. R., & Roux, C. W. L.
- Affiliations
- University College Dublin (IE)
- Corresponding author
- Dehestani, Babak
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2021-12-30
- Volume
- 30
- Issue
- 4
- Pages
- 320-325
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC8735818
- OpenAlex
- W4200574551
- Cited by
- 72
- References
- 38
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 16 · 2023: 12 · 2022: 5
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- amylin, amylin analogues, obesity treatment, pramlintide, cagrilintide, amylin receptor, satiety, gastric emptying, weight loss, dietary intake, anti-obesity drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amylin as a Future Obesity Treatment. https://app.cochat.ai/papers/10.7570/jomes21071
- The paper
- Dehestani, B., Stratford, N. R., & Roux, C. W. L. (2021). Amylin as a Future Obesity Treatment. Journal of Obesity & Metabolic Syndrome. https://doi.org/10.7570/jomes21071
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.